HUMANWELL HEALTHCARE (GROUP) CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.75 CNY | +1.97% |
|
+4.69% | -16.53% |
| Mar. 29 | Humanwell Healthcare's Profit Drops, Operating Income Climbs in 2023 | MT |
| Mar. 28 | Humanwell Healthcare Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -16.53% | 4.52B | B- | ||
| +24.17% | 562B | B | ||
| -6.43% | 358B | C+ | ||
| +19.07% | 322B | B- | ||
| +7.71% | 297B | C+ | ||
| +13.45% | 219B | B+ | ||
| +6.04% | 199B | B- | ||
| -10.51% | 196B | A+ | ||
| -11.41% | 149B | C+ | ||
| -6.93% | 146B | C+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
-
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
Divergence of Target Price
-
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 600079 Stock
- Ratings Humanwell Healthcare (Group) Co.,Ltd.
